On June 4, 2019 Cofactor Genomics, pioneers in the field of Predictive Immune Modeling, reported that they have become a member of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium with the goal of advancing the adoption of multidimensional biomarkers in cancer and immune-related diseases (Press release, Cofactor Genomics, JUN 4, 2019, View Source [SID1234536892]).
Formally launched in 2006, the FNIH Biomarkers Consortium is a major public-private biomedical research partnership managed by the FNIH with broad participation from stakeholders across biomedical research, including government, industry, academia and patient advocacy and other not-for-profit organizations. In addition to the FNIH, founding members include the National Institutes of Health (NIH), the Food and Drug Administration (FDA), the Pharmaceutical Research and Manufacturers of America, the Centers for Medicare & Medicaid Services (CMS) and BIO. The FNIH Biomarkers Consortium brings together the expertise and resources of various partners to rapidly identify, develop and seek qualification of potential high-impact biomarkers particularly to enable improvements in drug development, clinical care and regulatory decision-making.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Cofactor is pleased to be working together alongside the FNIH, NIH and FDA to accomplish our shared goals of improving predictive medicine through advanced biomarkers," said Cofactor CEO, Jarret Glasscock. "While other technologies stop at delivering data that require additional analysis or interpretation, we’re eager to see how Predictive Immune Modeling can fast track some of the valuable information these project teams have been seeking."
Cofactor’s success in demonstrating the utility of Predictive Immune Modeling with their ImmunoPrism assay positions them to add value to a number of the initiatives of the FNIH Biomarkers Consortium, specifically in the area of inflammation, immunity and cancer. Cofactor’s technical teams will participate in the FNIH Biomarkers Consortium and offer expertise in ImmunoPrism reagents and services to achieve advanced profiling of immune response.
"We are delighted to welcome Cofactor as the newest member of the FNIH Biomarkers Consortium and to further our work with their unique expertise in harnessing RNA data to drive multidimensional biomarker discovery," said Joseph P. Menetski, Ph.D., Associate Vice President for Research Partnerships, FNIH. "We could not accomplish our mission without the partnership of organizations like Cofactor that understand the importance of advancing biomarker research and its impact on precision medicine."
The FNIH Biomarkers Consortium is helping create a new era of precision medicine, with more highly predictive markers that have a direct impact on patients. Its goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines and therapies for prevention, early detection, diagnosis and treatment of disease.
Cofactor’s Chief Scientific Officer, Jon Armstrong, will present on the power of Predictive Immune Modeling in the Translational Science & Emerging Biomarkers track at the IO Combinations 360° meeting to be held June 20-21 in Philadelphia. Clients and collaborators of Cofactor can register for the event at a 25% discount using code CFG25.